Form 8-K - Current report:
SEC Accession No. 0001104659-23-116745
Filing Date
2023-11-13
Accepted
2023-11-13 08:06:57
Documents
14
Period of Report
2023-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FROM 8-K tm2330441d1_8k.htm   iXBRL 8-K 28536
2 EXHIBIT 99.1 tm2330441d1_ex99-1.htm EX-99.1 67009
6 GRAPHIC tm2330441d1_ex99-1img001.jpg GRAPHIC 72260
  Complete submission text file 0001104659-23-116745.txt   379471

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA atxs-20231113.xsd EX-101.SCH 3018
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE atxs-20231113_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atxs-20231113_pre.xml EX-101.PRE 22361
8 EXTRACTED XBRL INSTANCE DOCUMENT tm2330441d1_8k_htm.xml XML 3325
Mailing Address 75 STATE STREET SUITE 1400 BOSTON MA 02109
Business Address 75 STATE STREET SUITE 1400 BOSTON MA 02109 617-349-1971
Astria Therapeutics, Inc. (Filer) CIK: 0001454789 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37467 | Film No.: 231395277
SIC: 2834 Pharmaceutical Preparations